Capecitabine

Generic Name
Capecitabine
Brand Names
Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
Drug Type
Small Molecule
Chemical Formula
C15H22FN3O6
CAS Number
154361-50-9
Unique Ingredient Identifier
6804DJ8Z9U
Background

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication

Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions
Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
Associated Therapies
Chemotherapy
Clinical Trials
Related News

Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

Phase 1
Completed
Conditions
Colorectal Cancer
First Posted Date
2004-07-12
Last Posted Date
2013-03-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
37
Registration Number
NCT00086931
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

Phase 1
Terminated
Conditions
Colorectal Cancer
First Posted Date
2004-07-12
Last Posted Date
2013-02-01
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
10
Registration Number
NCT00087334
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Capecitabine
Drug: Imatinib mesylate
First Posted Date
2004-07-12
Last Posted Date
2014-06-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT00087152

GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors

First Posted Date
2004-06-11
Last Posted Date
2013-03-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00084643
Locations
🇺🇸

City of Hope, Duarte, California, United States

Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors

First Posted Date
2004-06-11
Last Posted Date
2023-08-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
61
Registration Number
NCT00084734
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

Phase 1
Completed
Conditions
Colorectal Cancer
First Posted Date
2004-06-11
Last Posted Date
2010-02-12
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00084591
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

First Posted Date
2004-06-11
Last Posted Date
2012-01-12
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00084942
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

First Posted Date
2004-06-11
Last Posted Date
2015-05-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
39
Registration Number
NCT00084617
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2004-05-25
Last Posted Date
2013-06-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00004012
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2004-05-17
Last Posted Date
2011-03-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
12
Registration Number
NCT00083148
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy